Published in Curr Med Res Opin on May 01, 2007
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Pro-inflammatory action of Candida albicans DNA in zymosan-induced arthritis. Inflamm Res (2012) 0.75
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis (2006) 5.27
Vancomycin: we can't get there from here. Clin Infect Dis (2011) 2.53
Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 2.18
Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. Am J Med (2008) 2.10
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer (2014) 1.98
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther (2006) 1.84
Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy (2007) 1.83
Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med (2002) 1.74
Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology (2009) 1.69
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother (2010) 1.69
The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med (2005) 1.67
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother (2006) 1.62
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother (2012) 1.33
Research publication by pharmacist authors in major medical journals: changes over a 10-year interval. Pharmacotherapy (2008) 1.27
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis (2008) 1.15
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2007) 1.14
Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy (2007) 1.14
Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm (2009) 1.13
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Impact of surgical site infections on length of stay and costs in selected colorectal procedures. Surg Infect (Larchmt) (2009) 1.11
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
A nationwide analysis of antibiotic use in hospice care in the final week of life. J Pain Symptom Manage (2013) 1.07
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother (2012) 1.06
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother (2012) 1.05
Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother (2003) 1.05
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis (2009) 0.99
Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol (2006) 0.98
Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy (2014) 0.98
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther Clin Risk Manag (2008) 0.97
Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf (2007) 0.96
National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm (2014) 0.95
Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy (2002) 0.95
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother (2011) 0.94
Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis (2006) 0.94
Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm (2004) 0.93
A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. Prev Chronic Dis (2004) 0.93
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis (2012) 0.91
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents (2007) 0.91
A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ (2013) 0.90
Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract (2013) 0.90
Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort. Clin Ther (2006) 0.90
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm (2007) 0.89
Pharmacist-physician collaboration for diabetes care: the diabetes initiative program. Ann Pharmacother (2013) 0.89
Defining success in diabetes disease management: digging deeper in the data. Dis Manag (2008) 0.88
A comparison of direct medical costs across racial and ethnic groups among children with cancer. Curr Med Res Opin (2008) 0.88
Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci (2003) 0.87
Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses (2011) 0.87
Neutropenia after single-dose clindamycin for dental prophylaxis. Pharmacotherapy (2003) 0.87
Variation in antibiotic treatment for diabetic patients with serious foot infections: a retrospective observational study. BMC Health Serv Res (2010) 0.87
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health (2011) 0.87
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai (2011) 0.86
Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother (2006) 0.85
Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. Paediatr Drugs (2002) 0.84
Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother (2012) 0.83
The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother (2012) 0.83
Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. Res Social Adm Pharm (2008) 0.83
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother (2013) 0.82
Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs (2010) 0.82
Risk factors associated with linezolid-nonsusceptible enterococcal infections. Am J Infect Control (2012) 0.81
Sustainability of Improved Glycemic Control After Diabetes Self-Management Education. Diabetes Spectr (2014) 0.81
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther (2010) 0.81
Diabetes disease management in Medicaid managed care: a program evaluation. Dis Manag (2006) 0.81
Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis. Case report. Neurosurg Focus (2004) 0.81
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg (2005) 0.80
Evaluation of doripenem utilization and susceptibilities at a large urban hospital. Int J Clin Pharm (2011) 0.80
Vancomycin dosing in children and young adults: back to the drawing board. Pharmacotherapy (2013) 0.80
Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis. Ann Pharmacother (2004) 0.80
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother (2010) 0.80
Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol (2012) 0.79
Comparison of antibiograms developed for inpatients and primary care outpatients. Diagn Microbiol Infect Dis (2013) 0.79
Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care (2004) 0.79
Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl) (2013) 0.79
Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses (2006) 0.79
Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother (2013) 0.79
Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm (2010) 0.79
Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis (2003) 0.79
Pharmacist-physician collaboration for diabetes care: cardiovascular outcomes. Ann Pharmacother (2013) 0.78
Impact of a pharmacotherapy alerting system on medication errors. Am J Health Syst Pharm (2013) 0.78
Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol (2010) 0.78
The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol (2011) 0.77
Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother (2010) 0.77
Use of electronic health record data to identify skin and soft tissue infections in primary care settings: a validation study. BMC Infect Dis (2013) 0.77
Methods to identify and compare parenteral nutrition administered from hospital-compounded and premixed multichamber bags in a retrospective hospital claims database. JPEN J Parenter Enteral Nutr (2011) 0.77
Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery. Surg Infect (Larchmt) (2008) 0.77